One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Sol-Gel Technologies Ltd. logo
Sol-Gel Technologies Ltd. SLGL
$ 61.62 -2.21%
report update icon

Quarterly report 2025-Q4
added 05-28-2026

Sol-Gel Technologies Ltd. Financial Ratios 2025-2011 | SLGL

Brief overview of Sol-Gel Technologies Ltd.'s market valuation

Ratios are assessed across five available annual reports in the 2021–2025 interval.

Key multiples at the end of the period are P/S 10.49x (median 5.14x), P/B 8.91x (median 1.51x). Valuation is 297.7% above five-year reference levels. The premium requires support from earnings and returns.

Capital efficiency is characterized by ROE -26.9%, ROA -20.5%, ROCE -31.7%. Current return ratios are negative, materially weakening the fundamental profile.

The cash cycle accelerated by 36.5 days to 52.4 days. Less capital is tied up in operations.

Overall assessment

Sol-Gel Technologies Ltd.'s valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.

Annual Financial Ratios Sol-Gel Technologies Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-33.2 -0.1 -0.1 -4.3 49.9 -7.5 -10.2 -3.3 -0.5 - - - - - -

P/S

10.5 0.1 1.7 16.4 5.1 25.0 10.9 829.7 99.4 - - - - - -

EPS

-2.2 -3.8 -10.0 -0.7 0.1 -1.3 -1.3 1.8 5.0 3.3 1.5 - - - -

EV (Enterprise Value)

199 M -11.2 M 1.78 M 55.6 M 154 M 221 M 250 M 107 M 80.3 M 35.3 M 19.8 M - - - -

EBITDA per Share

-2.67 -4.23 -10.7 -0.68 0.17 -1.3 -1.28 -1.83 -4.95 - - - - - -

EV/EBITDA

-26.8 0.9 -0.1 -3.5 34.3 -7.3 -9.8 -3.1 - - - - - - -

PEG

-0.22 -0.0 -0.0 0.03 - 2.36 -0.34 1.3 - - - - - - -

P/B

8.9 0.0 0.1 1.5 2.9 4.3 4.8 1.7 -0.3 - - - - - -

P/CF

631.3 -0.1 -0.1 -6.7 -20.9 -8.7 -11.1 -4.6 -0.7 - - - - - -

ROE %

-26.86 -36.67 -70.48 -35.35 5.79 -57.60 -46.91 -50.39 59.90 - - - - - -

ROA %

-20.48 -29.52 -60.15 -32.00 4.66 -49.51 -40.14 -46.21 -206.12 - - - - - -

ROCE %

-31.74 -39.31 -71.89 -37.52 5.16 -56.83 -47.36 -51.74 60.96 - - - - - -

Current Ratio

4.2 5.1 6.8 10.6 5.1 7.1 6.9 12.1 0.2 - - - - - -

DSO

52.4 62.8 967.1 983.4 88.8 130.5 32.8 - - - - - - - -

Operating Cycle

52.4 62.8 967.1 983.4 88.8 130.5 32.8 - - - - - - - -

Cash Conversion Cycle

52.4 62.8 967.1 983.4 88.8 130.5 32.8 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Sol-Gel Technologies Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-2.19 4.17 -3.79 0.07 -10.01 0.22 - - - - - - 0.35 - - - 0.31 - - - 0.26 - - - 0.36 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-2.67 4.06 -4.23 0.06 -10.7 -0.23 - - - - - - -0.35 - - - -0.33 - - - -0.28 - - - -0.38 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-21.46 -65.08 -113.86 -97.65 -114.10 -52.62 -40.26 -40.26 -40.26 -40.26 -40.26 -40.26 -48.73 -28.26 -28.26 -28.26 -10.79 - - - -9.00 - - - -8.47 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-15.75 -55.42 -95.79 -83.59 -97.76 -45.39 -34.56 -34.56 -34.56 -34.56 -34.56 -34.56 -17.31 - - - -9.47 - - - -7.77 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-33.95 -74.10 -119.99 -100.18 -115.74 -53.28 -40.08 -40.08 -40.08 -40.08 -40.08 -40.08 -49.02 -29.52 -29.52 -29.52 -11.15 - - - -9.43 - - - -8.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

4.2 5.3 5.1 5.9 6.8 8.1 - - - - 5.1 - 6.5 - 7.1 - 8.2 - 6.9 - 7.3 - 12.1 - - - 0.2 - - - 0.3 - - - - - - - - - - - - - - - - - - - - - - -

DSO

28.3 36.0 38.2 54.0 75.8 169.4 - - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - - - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - - - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Sol-Gel Technologies Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.94 2.79 % $ 48.1 M israelIsrael
Edesa Biotech Edesa Biotech
EDSA
$ 2.19 2.67 % $ 12.4 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.15 -1.6 % $ 126 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 14.49 4.4 % $ 937 M usaUSA
Moderna Moderna
MRNA
$ 253.93 5.17 % $ 98.8 B usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.55 -9.36 % $ 1.04 B israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.75 5.8 % $ 294 M usaUSA
Amgen Amgen
AMGN
$ 460.27 0.28 % $ 248 B usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.37 12.33 % $ 122 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 132.34 1.95 % $ 6.58 B usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.8 0.85 % $ 66.4 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Immunic Immunic
IMUX
$ 7.79 6.42 % $ 1.21 B usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.23 5.69 % $ 225 M schweizSchweiz
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.64 4.12 % $ 38.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Precision BioSciences Precision BioSciences
DTIL
$ 10.62 7.6 % $ 136 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.16 4.41 % $ 259 K usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 256.91 1.37 % $ 15.6 B danmarkDanmark
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 67.32 -3.3 % $ 1.35 B usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.42 9.23 % $ 44.3 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.29 2.38 % $ 343 M britainBritain
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 74.28 0.01 % $ 14.2 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.69 0.72 % $ 1.61 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.6 3.45 % $ 249 M britainBritain
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.77 2.9 % $ 90.2 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.59 -5.24 % $ 3.26 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.09 5.83 % $ 109 M franceFrance
BeyondSpring BeyondSpring
BYSI
$ 0.61 -3.32 % $ 25.1 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 45.88 3.01 % $ 7.56 B irlandaIrlanda
Altimmune Altimmune
ALT
$ 2.09 6.09 % $ 184 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.8 5.3 % $ 53.5 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.55 -1.2 % $ 6.09 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 10.35 10.52 % $ 283 M israelIsrael
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 58.16 1.22 % $ 7.78 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 119.79 1.51 % $ 23.4 B usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 7.81 -1.88 % $ 98 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.32 0.68 % $ 2.19 B canadaCanada
Cullinan Management Cullinan Management
CGEM
$ 11.37 5.28 % $ 685 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 87.46 1.86 % $ 21.1 B germanyGermany
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.19 -3.86 % $ 766 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 3.07 7.34 % $ 40.9 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.26 -0.79 % $ 57.6 M israelIsrael
AnaptysBio AnaptysBio
ANAB
$ 46.46 1.92 % $ 1.35 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 20.43 2.17 % $ 229 M usaUSA
Adagene Adagene
ADAG
$ 1.99 -1.73 % $ 117 M chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.51 10.07 % $ 443 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.09 1.88 % $ 3.47 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.55 -0.2 % $ 4.79 B irlandaIrlanda
Editas Medicine Editas Medicine
EDIT
$ 2.57 0.59 % $ 228 M usaUSA